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Background. Previous observations found a high prevalence of obstructive sleep apnea (OSA) in the hemodialysis population,
but the best diagnostic approach remains undefined. We assessed OSA prevalence and performance of available screening tools
to propose a specific diagnostic algorithm. Methods. 104 patients from 6 Swiss hemodialysis centers underwent polygraphy and
completed 3 OSA screening scores: STOP-BANG, Berlin’s Questionnaire, and Adjusted Neck Circumference. The OSA predictors
were identified on a derivation population and used to develop the diagnostic algorithm, which was validated on an independent
population. Results. We found 56% OSA prevalence (AHI ≥ 15/h), which was largely underdiagnosed. Screening scores showed
poor performance for OSA screening (ROC areas 0.538 [SE 0.093] to 0.655 [SE 0.083]). Age, neck circumference, and time on renal
replacement therapy were the best predictors of OSA and were used to develop a screening algorithm, with higher discriminatory
performance than classical screening tools (ROC area 0.831 [0.066]). Conclusions. Our study confirms the high OSA prevalence
and highlights the low diagnosis rate of this treatable cardiovascular risk factor in the hemodialysis population. Considering the
poor performance of OSA screening tools, we propose and validate a specific algorithm to identify hemodialysis patients at risk for
OSA for whom further sleep investigations should be considered.
1. Introduction
Sleep complaints are common in hemodialysis (HD) patients,
with a reported prevalence of 50 to 80% [1, 2], including
insomnia, sleep apnea (comprising the obstructive and the
central form), and restless legs syndrome as themost frequent
manifestations.
The reported prevalence of obstructive sleep apnea (OSA)
inHDpopulations is highly variable, ranging from 20 to 80%,
owing to differences in the studied populations, diagnostic
tools, and OSA definitions [1–7].
Despite these large differences, the prevalence of OSA
in HD patients appears to be remarkably higher than in
the general population, which has been reported to be 5 to
34% [8–11]. Studies in the general population revealed an
important proportion of undiagnosed cases [8–10], which is
probably also the case in the HD population.
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OSA causes a disruption of sleep, leading to daytime
symptoms, such as excessive daytime sleepiness [12, 13]. In
the meantime, repeated oxygen saturation drops increase the
oxidative stress and stimulate the sympathetic system, leading
to hypertension and an increased cardiovascular risk [14–16].
Diagnosing OSA is therefore important in the management
of HD patients with high cardiovascular morbidity and
mortality, since it is a treatable condition.
The clinical presentation of OSA in HD patients differs
from its presentation in patients without end-stage renal
disease (ESRD). As such, classical symptoms such as loud
snoring seem to be less often present, whereas others (hyper-
tension and fatigue) are common in hemodialysis patients
[17, 18]. Usual screening tools for OSA are mainly based on
these symptoms and might therefore be less accurate in HD
patients than in the general population.
The aims of this study were to assess the prevalence of
OSA in a European HD population to evaluate the predictive
value of classical screening tools and to develop a specific
diagnostic algorithm for HD patients.
2. Materials and Methods
2.1. Patients. Between June 2012 and June 2013, all the
patients attending 6 hemodialysis centers in the western part
of Switzerland were offered to be screened for OSA if they
fulfilled the inclusion criteria. Participating centers were one
university hospital department, 4 hemodialysis units located
in peripheral hospitals, and one private dialysis center.
Inclusion criteria were being on chronic intermittent
hemodialysis, age ≥18 years, and agreement to participate
in the study. Patients were excluded if they had decompen-
sated congestive heart failure or cognitive impairment/active
psychiatric disease limiting their ability to understand the
questionnaires.
2.2. Study Protocol. We conducted a multicenter, cross-sec-
tional population study.
Each participant underwent a nocturnal polygraphy and
completed a set of questionnaires.
Anthropometric parametersweremeasured; patients per-
formed a 24 h urine collection to quantify residual diuresis
and underwent a complete laboratory analysis.
The study complied with the Declaration of Helsinki
and was approved by the Institutional Ethics Committee
(Commission d’e´thique de la recherche clinique, Lausanne,
Switzerland). All participants provided written informed
consent.
2.3. Questionnaires and OSA Screening Scores. Patients com-
pleted a set of questionnaires during the dialysis session.
Daytime sleepiness was evaluated by the Epworth Sleepi-
ness Scale (ESS), using a cut-off value of >10 points to define
excessive daytime sleepiness [12, 19]. The subjective sleep
quality item of the Pittsburgh Sleep Quality Index was used
to assess sleep quality [20]. Data on sleep medications (hyp-
notics and benzodiazepines) taken before the sleep recording
were collected in the morning.
The screening scores for OSA were Berlin Questionnaire,
STOP-BANG score, and Adjusted Neck Circumference.
Berlin Questionnaire (BQ) consists of 11 items covering
3 categories (snoring, sleepiness, and hypertension/obesity).
Patients are considered at risk for OSA if 2 or more categories
are positive [21].
The STOP-BANG score consists of 8 items (snoring,
tiredness, observed sleep apnea, pressure (hypertension),
BMI > 35 kg/m2, age > 50 years, neck circumference > 40 cm,
and male gender). Each positive item adds 1 point; a score ≥
3 out of 8 is considered high risk for OSA [22].
The Adjusted Neck Circumference (ANC) is calculated
by measuring the patient’s neck circumference (in cm) and
adding additional centimeters if hypertension (4 cm), snoring
(3 cm), and nocturnal choking (3 cm) are present. An ANC
>48 cm indicates a high probability of OSA [23, 24].
2.4. Nocturnal Polygraphy. Nocturnal Home Polygraphy (PG)
was performed on the night preceding hemodialysis using an
Apnea Link Plus device (ResMed Corporation, San Diego,
CA, USA) including a chest motion band, a finger pulse
oximetry, and a nasal pressure cannula to analyze respiration.
All respiratory events were manually scored by the same
experienced pulmonologist (AO) according to the Ameri-
can Academy of Sleep Medicine criteria [25]. The Apnea-
Hypopnea Index (AHI) was calculated as the number of
apneas and hypopneas per hour of recording, and OSA
diagnosis was retained for AHI ≥ 15/h (moderate to severe
OSA).
2.5. Anthropometric Parameters. Neck circumference was
measured in the sitting position with a nonstretchable tape
above the cricothyroid membrane just before the hemodialy-
sis session following PG recording.
Weight was measured at the end of the hemodialysis
session to reflect nutritional status, in light indoor clothing
without shoes, using a calibrated Seca scale and height was
measured to the nearest centimeter using a wall-mounted
stadiometer.
BMI was calculated as weight divided by height in square
meters. Obesity was defined as a BMI ≥ 30 kg/m2 [26].
Hypertension was defined as previous diagnosed hyper-
tension or ongoing antihypertensive treatment.
2.6. Hemodialysis Characteristics. Thehemodialysis schedule
was not altered by the participation in the present study.
All the patients underwent thrice weekly hemodialysis; HD
sessions of the participating centers were performed during
the morning or afternoon; there were no evening shifts. The
hemodialysis efficacy was assessed using urea kinetic mod-
elling and expressed as equilibrated Kt/V (eKt/V), according
to the KDOQI recommendations [27]. Interdialytic weight
gain was used to account for the fluid state variation due
to HD and computed as the weight difference between
beginning and end of the HD session that followed PG.
2.7. Statistical Analysis. Statistical analysis was conducted
using Stata 11.0 for Windows (StataCorp LP, College Station,
BioMed Research International 3
TX, USA). t-test, chi-square test, andWilcoxon rank sum test
were used to compare the characteristics of the patients with
and without OSA. Statistical significance was established at
𝑝 < 0.05.
The performance of the different screening tools to pre-
dict the presence ofOSA, as diagnosed by PG,was assessed by
computing sensitivity, specificity, and positive and negative
predictive values.
A study population of 100 subjects was calculated as
necessary to detect OSA with 80% sensitivity with 5% alpha
error and 10% precision, assuming a 57% prevalence of OSA
[7].
ROC analysis was performed to evaluate the overall
performance of the screening tests. Subjects with Cheyne-
Stokes respiration were not considered in the evaluation of
the OSA screening tools.
In order to develop and validate a new diagnostic algo-
rithm for OSA, the patients were divided in a derivation
population (all patients from the hemodialysis unit of the
University Hospital of Lausanne, the main study center) and
an independent validation population (all patients from the
other centers).
A predictive logistic regression model was fitted to the
derivation set, including all the variables present in classical
screening scores: age, gender, BMI, neck circumference,
hypertension, daytime sleepiness, snoring, and unrefreshing
sleep (Model 1). A second prediction model (Model 2) was
fitted using the most significant factors from Model 1 (with
𝑝 < 0.20) and stepwise adding hemodialysis characteristics
to maximize both discriminatory accuracy (evaluated by
the area under ROC curve) and goodness of fit (Hosmer-
Lemeshow test).
The factors identified in Model 2 were entered in a
classification and regression tree analysis (CART, a chi-square
based nonparametric technique) to evaluate the best discrim-
inatory factors and cut-offs in a classification algorithm of the
observations.
Based on the results of the CART analysis, we developed
a screening algorithm to identify the patients at risk for OSA
and we assessed its performance by computing sensitivity,
specificity, positive and negative predictive values, and area
under ROC curve in the validation population.
3. Results
3.1. Study Population. Of the 235 screened candidates, 35
were not eligible and 75 declined to participate.
125 patients were included in the study. 104 subjects
(66 men and 38 women) completed home PG and were
considered for the final analysis. Reasons for dropout were
withdrawal of consent (13), technical problems with the PG
recording (3), and loss to follow-up before completing PG
(3 patients died, 1 was transplanted, and 1 was transferred to
another HD unit).
Patients who completed the study were younger (61.7 ±
14.9 versus 69.2 ± 16.1 years, 𝑝 < 0.01); there was no differ-
ence in sex distribution, time on renal replacement therapy,
sleep quality, and daytime sleepiness. For all 3 calculated
screening scores for OSA, the proportion of positive tests was
similar in patients who completed the study and in those who
did not.
Demographic, anthropometric, and medical data of the
studied population are detailed in Table 1.
3.2. Prevalence of Sleep Apnea and Associated Clinical Fea-
tures. Only 14% (15 patients) had a normal polygraphy (AHI
< 5/h); 30% had mild OSA (AHI 5–15/h), 25% had moderate
OSA (AHI 15–30/h), and 31% had severe OSA (AHI ≥ 30/h).
11 out of 58 patients (19%) withmoderate to severe OSA (AHI
≥ 15/h) had been previously diagnosed and only 6 (10%) were
already treated.
Four out of 104 patients (4% of the population) had a
central sleep apnea with a Cheyne-Stokes respiratory pattern.
Sleep related symptoms were present in a minority of
the study population and did not significantly differ between
patients with and without OSA (Table 1). Patients with OSA
were older and more often men and had a larger neck
circumference. Hypertension was highly prevalent (91%) in
the study population but not significantly different between
patients with and without OSA.
Among the characteristics of kidney disease and
hemodialysis, only time on renal replacement therapy (RRT)
differentiated the 2 populations, with OSA patients being on
RRT for a longer time.
3.3. Performance of the Usual Screening Instruments for OSA.
The performances of the 3 existing screening scores are
reported in Table 2.
Berlin’s Questionnaire (BQ) was positive in 49 patients,
classifying them at high risk of having OSA. Only 28 (57%)
out of these patients had an AHI ≥ 15/h, corresponding to a
positive predictive value (PPV) of 57%.
STOP-BANG score had a higher sensitivity, assigning 67
patients to the group having high risk of OSA. 71% of the
patients were correctly classified.
Twenty patients had an Adjusted Neck Circumference
(ANC) > 48 cm. This score had the highest specificity of the
3 tests but demonstrated a very poor sensitivity.
When the usual cut-off value of the tests was not con-
sidered and all tests were compared using a ROC analysis,
the STOP-BANG score and the ANC showed a similar
performance, with a ROC area of 0.652 [SE 0.085] and 0.655
[SE 0.083], respectively, whereas Berlin’s Questionnaire was
less accurate with a ROC area of 0.538 [SE 0.093].
3.4. Prediction of OSA in the Hemodialysis Population. The
characteristics of the derivation and validation populations
are summarized in Supplementary Table S1 in Supplementary
Material available online at http://dx.doi.org/10.1155/2015/
103686.
In the multivariate model based on the factors of classical
screening scores (Model 1), only age, neck circumference, and
hypertension were significantly associated with OSA, while
BMI and sleep related symptoms showed a nonsignificant
association (Table 3). The addition of hemodialysis-related
factors (Model 2) improved the discriminatory accuracy and
precision of the model.
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Table 1: Characteristics of the study population.
All Moderate to severe OSA(AHI ≥ 15/h)
No or mild OSA
(AHI < 15/h) 𝑝
𝑁 104 58 46
Demographic
Age (y) 61.7 (14.9) 65.2 (14.1) 57.3 (14.8) 0.007
Male sex (𝑁, %) 66 (63.5) 44 (75.9) 22 (47.8) 0.003
Ethnicity (𝑁, %)
Caucasian 84 (80.8) 49 (84.5) 35 (76.1)
0.545Asian 4 (3.8) 2 (3.4) 2 (4.4)
African 15 (15.4) 7 (12.1) 9 (19.6)
BMI (kg/m2) 26.1 (4.6) 26.6 (4.4) 25.5 (4.8) 0.217
Neck circumference (cm) 40.4 (4.4) 42.0 (3.8) 38.4 (4.3) <0.001
Obesity (BMI ≥ 30 kg/m2) (𝑁, %) 21 (20.2) 13 (22.4) 8 (17.4) 0.526
Hypertension (𝑁, %) 95 (91.4) 54 (93.1) 41 (89.1) 0.474
Hemodialysis
Time on RRT (y) [median–IQR] 2.6 [0.9–6.5] 3.8 [1.2–10.3] 1.9 [0.9–3.8] 0.026
Residual diuresis (mL) 505 (751) 386 (563) 687 (953) 0.078
Interdialytic weight gain (kg) 0.97 (1.62) 0.99 (1.66) 0.95 (1.57) 0.908
HD duration per week (h)# 11.3 (1.0) 11.5 (0.8) 11.2 (1.2) 0.179
Morning HD shift (𝑁, %) 69 (66.4) 41 (70.7) 28 (60.9) 0.293
Hemodiafiltration (𝑁, %)# 25 (24.0) 12 (20.7) 13 (28.3) 0.369
HD access (𝑁, %):
Fistula 80 (76.9) 43 (74.1) 37 (80.4) 0.449
Catheter 24 (23.1) 15 (25.9) 9 (19.6)
eKt/V 1.51 (0.33) 1.47 (0.33) 1.56 (0.34) 0.203
Sleep
AHI (number/h) [median–IQR] 17.5 [7.0–40.0] 33.0 [22.0–52.0] 6.5 [4.0–10.0] <0.001
ODI (number/h) [median–IQR] 18.0 [9.0–39.0] 38.0 [20.0–49.0] 9.0 [6.8–13.0] <0.001
Epworth score [median–IQR] 5 [3–8] 5 [2–7] 5 [3–9] 0.247
Excessive daytime sleepiness (𝑁, %) 17 (16.4) 7 (12.1) 10 (21.7) 0.185
Sleep time (h) [median–IQR] 7 [6–8] 7 [6–8] 7 [6–8] 0.955
Poor sleep quality (𝑁, %) 31 (29.8) 18 (31.0) 13 (28.4) 0.759
Snoring (𝑁, %) 57 (54.8) 37 (63.8) 20 (43.5) 0.039
Unrefreshing sleep (𝑁, %) 35 (33.6) 19 (32.8) 16 (34.8) 0.828
Observed apneas (𝑁, %) 7 (6.7) 6 (10.3) 1 (2.2) 0.099
Restless legs syndrome (𝑁, %) 19 (19.0) 12 (22.2) 7 (15.2) 0.374
Use of sleep medications (𝑁, %) 17 (16.4) 7 (12.1) 10 (21.7) 0.285
Biology
Hemoglobin (g/L) 113.4 (12.3) 113.0 (12.9) 114.0 (11.8) 0.684
Phosphates (mmol/L) 1.49 (0.38) 1.43 (0.37) 1.57 (0.37) 0.072
Creatinine (mg/dL) 7.9 (2.3) 7.7 (2.4) 8.2 (2.2) 0.343
BUN (mg/dL) 54.6 (14.0) 54.0 (14.6) 55.2 (13.7) 0.730
Bicarbonates (mmol/L) 22.4 (2.4) 22.1 (2.7) 22.7 (2.0) 0.277
Values are expressed as mean (SD) if not otherwise specified. IQR: interquartile range.
OSA: obstructive sleep apnea; BMI: body mass index; RRT: renal replacement therapy; HD: hemodialysis; eKt/V: hemodialysis efficacy, assessed using urea
kinetic modelling; AHI: apnea/hypopnea index; ODI: oxygen desaturation index; BUN: blood urea nitrogen.
#All patients on thrice weekly HD with a synthetic HD membrane (polysulfone or polyethersulfone).
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Table 2: Performance of the screening instruments for OSA.
Test Sensitivity Specificity PPV NPV Accuracy
Berlin’s Questionnaire 51.9% [42.1–61.6] 54.4% [44.6–64.1] 57.1% [47.4–66.8] 49.0% [39.2–58.8] 53.0%
STOP-BANG 85.2% [78.2–92.2] 54.4% [44.6–64.1] 68.7% [59.6–77.8] 75.8% [67.4–84.2] 71.0%
Adjusted Neck Circumference 29.6% [20.7–38.6] 91.3% [85.8–96.8] 80.0 [72.2–87.8] 52.5% [42.7–62.3] 58.0%
ANT algorithm∗ 90.5% [81.7–99.2] 63.6% [49.3–78.0] 70.4% [56.7–84.0] 87.5% [77.6–97.4] 76.7%
Values are expressed as mean [95% CI].
PPV: positive predictive value; NPV: negative predictive value.
Accuracy: percentage of correctly classified subjects.
∗ANT algorithm applied to the validation population only.
Table 3: Multivariate logistic models for prediction of obstructive sleep apnea.
Factors Model 1 Model 2 ROC area Hosmer-Lemeshow
OR 95% CI OR 95% CI
Gender (f) 0.72∗ 0.12–4.20
Age (y) 1.10 1.02–1.19 1.12 1.02–1.22
Neck circumference (cm) 1.65 1.16–2.36 1.63 1.13–2.34
Hypertension 147 2–11613 379 2–87016
BMI (kg/m2) 0.87∗ 0.68–1.10
Daytime sleepiness 0.58∗ 0.08–4.32
Snoring 3.91 0.56–27.2 6.57 0.71–60.71
Unrefreshing sleep 0.26 0.04–1.78 0.10 0.01–1.11 0.900 0.010
eKt/V 0.08 0.00–14.09 0.927 0.259
Time on RRT 1.06 0.92–1.21 0.927 0.387
Model 1: prediction model with classical risk factors (∗𝑝 > 0.20).
Model 2: specific prediction model: significant factors of Model 1 (𝑝 < 0.20) + stepwise addition of hemodialysis characteristics to maximize discriminatory
accuracy (ROC area) and goodness of fit (Hosmer-Lemeshow test).
OR: Odds Ratio and 95% CI in the final cumulative model.
ROC area: area under the ROC curve of the model when the factor is added.
Hosmer-Lemeshow test: goodness of fit of the model when the factor is added.
The classification and regression trees (CART) analysis
identified age > 70 years, neck circumference > 40 cm,
and time on RRT > 5 years as the best discriminatory
factors. These factors were used to create a specific screening
algorithm: the ANT algorithm (Figure 1).
The application of the ANT algorithm to the validation
population led to the categorization of 27 patients (63%) as
being at risk for OSA, with higher sensitivity and negative
predictive values than the classical screening tools (Table 2).
The proposed algorithm had 100% negative predictive value
for severe sleep apnea in both the derivation population and
the validation population (Figure 1).
On ROC analysis, the ANT algorithm performed signif-
icantly better than the 3 classical screening tools, showing a
ROC area of 0.831 [SE 0.066] when applied to the validation
population (Figure 2).
4. Discussion
This is the largest cohort study in Europe using an objective
method (polygraphy) instead of questionnaires to assess the
prevalence of OSA in ESRD patients undergoing hemodial-
ysis. The prevalence of moderate to severe OSA in this
population was 56%, and 31% of the subjects had severe
OSA (with a clear indication for treatment), but only a small
proportion of all OSA patients (19%) had been previously
diagnosed and even less (10%) were treated.
Theusual screening tools forOSA, Berlin’sQuestionnaire,
STOP-BANG score, and Adjusted Neck Circumference, per-
formed poorly in this population and thus appear to be inef-
fective in daily clinical practice. In this study, we developed
and validated a diagnostic algorithm specifically dedicated to
hemodialysis patients with a high sensitivity and predictive
value to help clinicians screen their patients for OSA.
The largest epidemiologic study in this field reported an
OSA prevalence of 23.6% using Berlin’s Questionnaire [1],
which may have underestimated the prevalence of this con-
dition considering its poor performance in the hemodialysis
population. The other trials were small studies with selective
recruitment of symptomatic patients [2–5], except for two
recent studies performed in USA and Canada in patients
with different degrees of chronic kidney disease attending
outpatient nephrology clinics [6, 7]. Both studies recruited a
subgroup of 75 patients on intermittent hemodialysis, inves-
tigated by home polysomnography in the American protocol
and by overnight respiratory monitoring in Canada. Our
results are in line with the reported prevalence ofmoderate to
severeOSAof 57% in theCanadian study and above the 25.7%
prevalence of severeOSA observed in theUS study.The lower
prevalence in the latter may be due to a less sensitive sensor
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Probability of OSA/severe OSA:
(i) Derivation pop. 74%/40%
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(ii) Validation pop. 12%/0%
>40 cm
≤40 cm
>70 y
≤70 y
>5 y
≤5 y
Figure 1: Proposed diagnostic algorithm (ANT algorithm). OSA: obstructive sleep apnea; Neck circum.: neck circumference; RRT: renal
replacement therapy. Further investigation by objective sleep recording may be indicated in the low-risk group according to the clinical
context (i.e., as a part of a presurgical assessment).
0.00
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0.50
0.75
1.00
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0.00 0.25 0.50 0.75 1.00
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ANT algorithm: AUC 0.831 [0.066]
STOP-BANG: AUC 0.652 [0.085]∗
ANC: AUC 0.655 [0.083]∗
Berlin: AUC 0.538 [0.093]∗∗
Figure 2: ROC curves of the different screening strategies (validation population). AUC: area under ROC curve [SE]. ∗𝑝 < 0.05 compared
to ANT algorithm (∗∗𝑝 < 0.01).
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(thermistor instead of nasal pressure) to assess breathing
patterns and to a more restrictive definition of hypopnea
requiring a 4% (instead of 3%) oxygen desaturation.
OSA is recognized as an important cardiovascular risk
factor in the general population [14, 15]. Although the
impact of OSA on clinical outcomes in hemodialysis patients
has not yet been evaluated in prospective studies, OSA is
likely to contribute to the increased cardiovascular morbidity
and mortality observed in this population [28–33]. With
such a high prevalence and these potential cardiovascular
consequences, OSA screening should be considered as part
of the usual workup of ESRD patients, since this condition
can be effectively treated with continuous positive airway
pressure (CPAP) [14, 34].
For the daily clinical practice, it is important to have
a simple tool allowing the patients to be quickly screened,
in order to refer those at risk of OSA for further testing.
Different OSA screening tools, in the form of questionnaires
or scores, have been developed and validated in the general
population for this purpose. According to our results, these
screening tools are less accurate in the hemodialysis popula-
tionwith poor sensitivity and specificity. For example, Berlin’s
Questionnaire showed 86% sensitivity and 77% specificity for
identifying subjects with AHI > 5/h in the general population
[21]. When applied to our hemodialysis population, the same
questionnaire performed remarkably worse, with a sensitivity
and a specificity just above 50% to identifymoderate to severe
OSA. Our results are in line with those of Nicholl et al. who
demonstrated an accuracy of the 3 screening tools (Berlin’s
Questionnaire, STOP-BANG, and ANC) ranging from 51 to
67% in the ESRD population [35]. However, they used a less
accurate reference test than in our study (simple oximetry
instead of polygraphy).
The poor performance of these screening tools in ESRD
patients can be explained by the fact that they are mostly
based on the typical clinical characteristics associated with
OSA, such as excessive daytime sleepiness, unrefreshing
sleep, obesity, and hypertension. In our population, the
prevalence of these symptoms was not different between sub-
jects with and without OSA, probably because other factors
related to renal failure contribute to their development. Our
observations support the fact that clinical parameters specific
to the hemodialysis population should be considered when
screening for OSA in this population. Among the HD related
parameters, time on renal replacement therapy emerged
as the one with the strongest association with OSA. This
effect was independent of age and represents a new finding,
suggesting that factors appearing late in the course of the
kidney disease could play a role in the increased prevalence of
OSA inHDpatients. One possible involvedmechanism could
be chronic fluid overload with overnight fluid displacement
to the neck soft tissues increasing upper airway collapse,
a phenomenon that has been documented by our research
group in hemodialysis patients with OSA [36]. In the present
study, neither residual diuresis nor interdialytic weight gain
was different between patients with and without OSA, but
no direct measurement of fluid overload was performed (i.e.,
by bioimpedance) and thus we cannot exclude the fact that
chronic fluid overload was present in the clinically estimated
post-HD “dry” weight. An alternative mechanism could
be a dysfunction of upper airway and respiratory muscles
secondary to chronic uremic neuropathy or myopathy [37,
38].
To address the limitations of classical screening tools,
we propose a simple screening algorithm, based on readily
available variables: age, neck circumference, and time on
renal replacement therapy. In our validation population,
the proposed screening algorithm performed considerably
better than usual screening tools, even when the tests were
compared by ROC analysis, considering different cut-offs.
This simple algorithm could be easily used by clinicians to
screen their patients for OSA and select those who need
further testing.
There are also limitations in our study that need to be
considered. First, although this is the largest study on a
hemodialysis population using nocturnal recordings, 31% of
the subjects declined to have a sleep recording, which may
have induced a selection bias. However, since patients who
refused the recording were older than those who accepted
and OSA tends to increase with age, this may have led to
an underestimation of OSA prevalence. This refusal rate also
highlights the fact that sleep recordings, although noninva-
sive, represent an important burden for hemodialysis patients
and the fact that a simple clinical algorithm like the one
we propose would be easier to use as a first line screening
tool. Second, even though we used independent groups of
patients for the creation and the validation of the ANT
algorithm, this screening strategy will need to be validated
in another population. However, since our population has
similar demographic and clinical features (28% of patients
with age > 70 years and 32% with a time on RRT > 5 years)
to the European hemodialysis population [30, 39, 40], we
believe that results of ANT algorithm in other populations
would probably be comparable.
Finally, we used ambulatory polygraphy instead of the
gold standard in-laboratory polysomnography. Even though
polygraphy is a recognized diagnostic tool for OSA, the
absence of an objective sleep duration measure by elec-
troencephalogram implies an AHI calculation based on the
recording time rather than sleep duration which is shorter.
As a consequence, severity and prevalence of OSA could
have been underestimated. On the opposite side, since all
recordingswere performed the night preceding hemodialysis,
OSA severity could have been overestimated considering the
negative effect of fluid overload onOSA. In effect, we recently
showed that OSA is more severe on nights preceding a
hemodialysis session in overhydrated patients and is reduced
by the correction of fluid overload with hemodialysis [36].
In conclusion, our study confirms the high prevalence of
OSA and highlights the low diagnosis and treatment rate of
this important cardiovascular risk factor in the hemodialysis
population.
Considering the poor performance of classical OSA
screening tools, we propose a simple screening algorithm
specific to the hemodialysis population to identify patients
at risk for OSA who need further testing. This diagnostic
approach warrants further prospective validation on a larger
8 BioMed Research International
population prior to introducing the algorithm into clinical
practice.
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